U S FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström s Macroglobulinemia pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysisBRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ETCAMBRIDGE, Mass. & BEIJING (BU.
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countriesBeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product salesBeiGene has the option.